Cannabinoid treats as adjunctive therapy for pets: gaps in our knowledge

References

• The Science Oakland, CA: Treatibles; [cited 2017 Nov 18]. Available from: https://www.treatibles.com/pages/new-the-science
   Google Scholar
• Hemp Genix. 2016. Available from: https://hempgenix.us/checkout/
   Google Scholar
• Canna-Pet. 2018. Available from: https://canna-pet.com/
   Google Scholar
• State Medical Marijuana Laws: National Conference of State Legislatures; [updated 2017 Sept 9; cited 2017 2017 Oct 9]. Available from: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx-4
   Google Scholar
• Small E, Cronquist A. A practical and natural taxonomy for cannabis. Taxon. 1976;25(4):405.
   Web of Science ®Google Scholar
• Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras PsiquiatrRev Bras Psiquiatr. 2008;30(3):271–280.
   PubMed Web of Science ®Google Scholar
• Phytochemistry & Compounds: Canna-Pet; [cited 2017 Nov 18]. Available from: https://canna-pet.com/our-products/phytochemistry-active-compounds/
   Google Scholar
• Nelson E. 2015. Canna Pet LLC 2/24/15 Silver Spring, MD: FDA; [cited 2017 18 Nov]. Available from: https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm435662.htm
   Google Scholar
• Administration USFaD. Warning letters test results for cannabidiol-related products; [cited 2018]. Available from: https://www.fda.gov/newsevents/publichealthfocus/ucm484109.htm
   Google Scholar
• Kogan LR, Hellyer PW, Robinson NG. Consumers' perceptions of hemp products for animals. J Am Holist Vet Med Assoc. 2016;42:40–48.
   Google Scholar
• Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64(1):21–47.
   PubMed Web of Science ®Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770–1804.
   PubMed Web of Science ®Google Scholar
• Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos. 1988;16(3):469–472.
   PubMed Web of Science ®Google Scholar
• Samara E, Bialer M, Harvey DJ. Identification of urinary metabolites of cannabidiol in the dog. Drug Metab Dispos. 1990;18(5):571–579.
   Web of Science ®Google Scholar
• Samara E, Bialer M, Harvey DJ. Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm Drug Dispos. 1990;11(9):785–795.
   Web of Science ®Google Scholar
• Nadulski T, Sporkert F, Schnelle M, et al., Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.J Anal Toxicology. 2005;29(8):782–789.
   PubMed Web of Science ®Google Scholar
• Brunet B, Doucet C, Venisse N, et al. Validation of large white pig as an animal model for the study of cannabinoids metabolism: application to the study of THC distribution in tissues. Forensic Sci Int. 2006;161(2–3):169–174.
   Web of Science ®Google Scholar
• Howlett AC, Abood ME. Chapter five - CB1 and CB2 receptor pharmacology. In: Kendall D, Alexander SPH, editors. Advances in pharmacology. Academic Press; Elsevier, San Diego, CA, USA. 2017;80: 169–206.
   Google Scholar
• Freundt-Revilla J, Kegler K, Baumgartner W, et al. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS One. 2017;12(7):e0181064.
   Web of Science ®Google Scholar
• Fernandez-Trapero M, Espejo-Porras F, Rodriguez-Cueto C, et al. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis Model Mech. 2017;10(5):551–558.
   Web of Science ®Google Scholar
• Gebremedhin D, Lange AR, Campbell WB, et al. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol Heart C. 1999;276(6):H2085–H2093.
   Web of Science ®Google Scholar
• Esposito G, Scuderi C, Valenza M, et al. Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One. 2011;6(12):e28668.
   PubMed Web of Science ®Google Scholar
• Xiong W, Cui T, Cheng K, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. J Exp Med. 2012;209(6):1121–1134.
   Web of Science ®Google Scholar
• Schier A, Ribeiro N, Coutinho D, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953–960.
   Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845–852.
   PubMed Web of Science ®Google Scholar
• Ryan D, Drysdale AJ, Lafourcade C, et al. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci. 2009;29(7):2053–2063.
   PubMed Web of Science ®Google Scholar
• Shirazi-zand Z, Ahmad-Molaei L, Motamedi F, et al. The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice. Epilepsy Behav. 2013;28(1):1–7.
   PubMed Web of Science ®Google Scholar
• Thompson GR, Rosenkrantz H, Schaeppi UH, et al. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol. 1973;25(3):363–372.
   PubMed Web of Science ®Google Scholar
• PubChem Compound Database; CID = 644019; [cited 2018 Jan 8]. Available from: https://pubchem.ncbi.nlm.nih.gov/
   Google Scholar
• Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic activity of Cytochrome P450 2C19. Drug Metab Pharmacokinet 2013;28(4):332–338.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15):730–736.
   Web of Science ®Google Scholar
• Sasaki K, Shimoda M. Possible drug–drug interaction in dogs and cats resulted from alteration in drug metabolism: a mini review. J Adv Res. 2015;6(3):383–392.
   PubMed Web of Science ®Google Scholar
• Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, et al. Safety and side effects of Cannabidiol, a Cannabis sativa constituent. Curr Drug Safety. 2011;6(4):237–249.
   PubMedGoogle Scholar
• Rieder SA, Chauhan A, Singh U, et al. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology. 2010;215(8):598–605.
   PubMed Web of Science ®Google Scholar
• GW announces new Epidiolex® (CBD) positive phase 3 data in Dravet Syndrome and Lennox-Gastaut Syndrome [Internet]. London: GW Pharmaceuticals; 2016; [cited Nov 18]. Available from: https://www.gwpharm.com/about-us/news/gw-announces-new-epidiolex%C2%AE-cbd-positive-phase-3-data-dravet-syndrome-and-lennox
   Google Scholar
• Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav. 2017;70:288–291.
   PubMed Web of Science ®Google Scholar